PARK7 and cancer: In addition to targeting the Trx system other molecules, e.g. the inhibition of the PTEN axis [217] or the protein deglycase DJ-1 (DJ-1) known to exhibit anti-oxidative and cyto-protective functions in other diseases [218–220] might have therapeutic potential, since DJ-1 is often upregulated in cancer cells and involved in the regulation of various redox stress responsive signaling pathways (PI3K/AKT/PKB; Trx1/ASK1) [217, 221].